Johnson & Johnson's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Tax-Provision" stands at 6.38 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value since 12/31/2018.
Johnson & Johnson's third quarter result of 2.34 Billion USD for the item "Tax Provision" represents an increase of 145.39 percent compared to it's second quarter result.
Also, Johnson & Johnson's third quarter result of 2.34 Billion USD for the item "Tax Provision" represents an increase of 263.51 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Johnson & Johnson's third quarter result of 6.38 Billion USD for the item "Tax Provision" represents an increase of 36.21 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 123.26 percent compared to the value the year prior.
The 1 year change in percent is 123.26.
The 3 year change in percent is 99.28.
The 5 year change in percent is 206.58.
The 10 year change in percent is 86.31.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Tax Provision | 905,699,262,464.00 |
![]() | AbbVie Inc - Tax Provision | 399,570,305,024.00 |
![]() | Roche Holding AG - Tax Provision | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Tax Provision | 280,205,508,085.11 |
![]() | Novartis AG - Tax Provision | 255,096,620,580.91 |